2018 CPDD Peer Reviewers.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 260, doi. 10.1002/cpdd.661
- Publication type:
- Article
Works matching IS 2160763X AND DT 2019 AND VI 8 AND IP 2
Results: 14
1
2
An Open‐Label, Randomized, Pivotal Bioequivalence Study of Oral Rolapitant.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 152, doi. 10.1002/cpdd.651
- By:
- Publication type:
- Article
3
Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 172, doi. 10.1002/cpdd.645
- By:
- Publication type:
- Article
4
Quantitative Assessment of the Effect of Chronic Kidney Disease on the Nonrenal Clearance of 10 Drugs After Intravenous Administration.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 138, doi. 10.1002/cpdd.635
- By:
- Publication type:
- Article
5
Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 246, doi. 10.1002/cpdd.604
- By:
- Publication type:
- Article
6
Open‐Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 188, doi. 10.1002/cpdd.603
- By:
- Publication type:
- Article
7
First‐in‐Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 234, doi. 10.1002/cpdd.600
- By:
- Publication type:
- Article
8
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 133, doi. 10.1002/cpdd.590
- Publication type:
- Article
9
Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 223, doi. 10.1002/cpdd.585
- By:
- Publication type:
- Article
10
Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 160, doi. 10.1002/cpdd.580
- By:
- Publication type:
- Article
11
Absolute Bioavailability of Osimertinib in Healthy Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 198, doi. 10.1002/cpdd.467
- By:
- Publication type:
- Article
12
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 179, doi. 10.1002/cpdd.463
- By:
- Publication type:
- Article
13
Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 208, doi. 10.1002/cpdd.462
- By:
- Publication type:
- Article
14
Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Male Volunteers: A Randomized, Single‐Dose, Two‐Period, Two‐Sequence Crossover Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 2, p. 217, doi. 10.1002/cpdd.450
- By:
- Publication type:
- Article